Introduction of Affordable Weight-Loss Solutions

The introduction of affordable weight-loss jabs has prompted drugmakers and packaged food companies to explore partnerships to offer nutrition products tailored for semaglutide patients. Key players in this area include Sun Pharma, Torrent, Zydus, Dr Reddy's, Glenmark, and Alkem, who have launched generics following Novo Nordisk's patent expiration.

Partnerships and Nutritional Products

• Companies are partnering with consumer goods firms to develop dietary support products.
• Dr Reddy's Labs has a joint venture with Nestle to create nutraceutical products.
• Mankind Pharma plans to establish a new division, Mankind Nutrition, focusing on obesity.

Impact of GLP-1 Receptor Agonists

Studies highlight that GLP-1 receptor agonists like semaglutide lead to significant lean muscle loss (25% to 40% of total weight loss), necessitating high protein supplements.

Market Expansion

According to PharmaTrac, the semaglutide market is expected to expand significantly, with the obesity drug segment projected to grow from ₹1,500 crore to ₹8,000 crore by 2030.

Opportunities for Packaged Foods Companies

• Weight-loss products present both challenges and opportunities for food companies.
• Amul, for example, is expanding its protein product portfolio to include new research-backed products.
• Companies are observing trends from the West, where appetite suppression drugs impact food consumption.

Shifts in Consumer Preferences

With appetite reduction from medications, consumers are focusing on the quality of food, preferring high-protein, fiber-rich, and functional foods for energy and muscle retention.

Future Trends

• Low-sugar, millet-based products have been a small part of food companies' portfolios but are expected to become more significant.
• Companies like Parle Products are investing in R&D to expand their offerings in this area.